Q-omics provides the consensus-scored ZNF274 profile across patient tissues and cancer cell-line models. ZNF274 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF274 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ZNF274 RNA expression shows 20,232 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where ZNF274 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF274 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF274 survival associations across molecular data types. ZNF274 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF274 RNA expression–survival associations across cancer types. High ZNF274 expression shows unfavorable associations in UVM and SKCM, but favorable associations in GBM, UCEC, UCS and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF274 RNA expression.
This table summarizes ZNF274 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF274. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF274 shows lower tumor expression in COAD, THCA, KICH, BLCA and UCEC and higher tumor expression in CHOL. The COAD box plot shows higher ZNF274 RNA expression in normal versus tumor tissue (log2 FC = −0.674, t-test p = .006).
This table shows molecular features associated with ZNF274 in patient tissues and cancer cell lines. In patient samples, ZNF274 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF274 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
